View source for 20240050442. TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER simplified abstract (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE)

=TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER=


==Organization Name==

[[:Category:CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE|CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE]]


[[Category:CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE]]

==Inventor(s)==

[[:Category:BARBARA Bardoni of NICE (FR)|BARBARA Bardoni of NICE (FR)]][[Category:BARBARA Bardoni of NICE (FR)]]

[[:Category:THOMAS Maurin of ANTIBES (FR)|THOMAS Maurin of ANTIBES (FR)]][[Category:THOMAS Maurin of ANTIBES (FR)]]

==TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER - A simplified explanation of the abstract==


This abstract first appeared for US patent application 20240050442 titled 'TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER

==Simplified Explanation==

The present invention is about trimeprazine derivatives that can be used to treat neuropsychiatric disorders such as intellectual disability (ID), fragile X syndrome (FXS), autism spectrum disorders (ASD), and attention deficit hyperactivity disorder (ADHD). The invention also includes pharmaceutical compositions containing these derivatives.

* Trimeprazine derivatives of formula (i) are used for treating neuropsychiatric disorders.
* The specific disorders that can be treated include intellectual disability (ID), fragile X syndrome (FXS), autism spectrum disorders (ASD), and attention deficit hyperactivity disorder (ADHD).
* The invention also includes pharmaceutical compositions that contain these trimeprazine derivatives.

== Potential Applications ==
* Treatment of intellectual disability (ID)
* Treatment of fragile X syndrome (FXS)
* Treatment of autism spectrum disorders (ASD)
* Treatment of attention deficit hyperactivity disorder (ADHD)

== Problems Solved ==
* Lack of effective treatments for intellectual disability (ID)
* Limited treatment options for fragile X syndrome (FXS)
* Limited treatment options for autism spectrum disorders (ASD)
* Limited treatment options for attention deficit hyperactivity disorder (ADHD)

== Benefits ==
* Provides a potential treatment option for intellectual disability (ID)
* Offers a new approach for treating fragile X syndrome (FXS)
* Provides a potential treatment option for autism spectrum disorders (ASD)
* Offers a new approach for treating attention deficit hyperactivity disorder (ADHD)


==Original Abstract Submitted==

the present invention relates to trimeprazine derivatives of formula (i) for use for treating a neuropsychiatric disorder chosen among an intellectual disability (id), preferably fragile x syndrome (fxs), autism spectrum disorders (asd), and attention deficit hyperactivity disorder (adid). the invention also relates to pharmaceutical compositions for use comprising such derivatives.



[[Category:A61K31/5415]]
[[Category:A61K9/00]]
[[Category:A61P25/00]]